E.B. Golden

ORCID: 0000-0002-1096-9806
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Lung Cancer Treatments and Mutations
  • Radiopharmaceutical Chemistry and Applications
  • Lung Cancer Research Studies
  • Breast Cancer Treatment Studies
  • Radiation Therapy and Dosimetry
  • HER2/EGFR in Cancer Research
  • Lung Cancer Diagnosis and Treatment
  • Effects of Radiation Exposure
  • Peptidase Inhibition and Analysis
  • Cancer, Stress, Anesthesia, and Immune Response
  • Advanced Radiotherapy Techniques
  • Glioma Diagnosis and Treatment
  • Intestinal and Peritoneal Adhesions
  • Medical Imaging Techniques and Applications
  • Minimally Invasive Surgical Techniques
  • Breast Lesions and Carcinomas
  • Glaucoma and retinal disorders
  • Immune Cell Function and Interaction
  • Neurosurgical Procedures and Complications
  • Endoplasmic Reticulum Stress and Disease
  • Occupational and environmental lung diseases
  • Genetic factors in colorectal cancer
  • BRCA gene mutations in cancer

Cornell University
2016-2024

Johns Hopkins University
2024

College Medical Center
2024

Presbyterian Hospital
2020

University of California, San Francisco
2018-2019

New York University
2011-2015

NYU Langone Health
2013

The sensitivity of contrast-enhanced 3D-FLAIR has not been assessed in patients with idiopathic intracranial hypertension. purpose this study was to evaluate whether hyperintensity the optic nerve/optic nerve head on imaging is associated papilledema hypertension.A retrospective review conducted from 2012 2015 clinically diagnosed hypertension and age- sex-matched controls who had MR 3D-FLAIR. Two neuroradiologists graded each a scale 0-3. This grade then correlated Frisén Scale, an...

10.3174/ajnr.a5937 article EN cc-by American Journal of Neuroradiology 2019-01-24

10.1016/j.ijrobp.2013.06.1663 article EN International Journal of Radiation Oncology*Biology*Physics 2013-09-20

Recent reports have shown an overall survival (OS) benefit to chemotherapy (CT) followed by (f/b) chest radiation therapy (RT) for patients with extensive-stage small cell lung cancer (ES-SCLC) (Slotman et al, Lancet 2015). Evidence also suggests superior outcomes concurrent chemoradiation (CRT) over a sequential regimen. In limited-stage SCLC (LS-SCLC), even timing of RT, given (as opposed after) the 1st two cycles CT, confers OS benefit; yet, no investigating use CT + RT as first-line...

10.1016/j.ijrobp.2015.07.389 article EN other-oa International Journal of Radiation Oncology*Biology*Physics 2015-10-17

10.1016/j.ijrobp.2013.06.1674 article EN International Journal of Radiation Oncology*Biology*Physics 2013-09-20

10.1016/j.ijrobp.2013.06.1675 article EN International Journal of Radiation Oncology*Biology*Physics 2013-09-20

10.1016/j.ijrobp.2018.07.154 article EN International Journal of Radiation Oncology*Biology*Physics 2018-10-19
Coming Soon ...